Ennature Bio Pharma Limited has successfully listed on the National Stock Exchange (NSE) and BSE Limited on November 4, 2026. The company operates in three segments: plant-based pharmaceutical ingredients (API), biopolymers, and nutraceuticals. In FY26, the biopharma division reported ₹246 crore in net revenue, with an EBITDA of ₹29 crore and a 40.1% gross margin. The API business, accounting for 67% of sales, serves over 150 customers in 26 countries, with exports at 54%. The biopolymer segment (16% of sales) focuses on guar and specialty gums, with exports at 69% to 23 countries. Nutraceuticals (17% of sales) is identified as a key growth driver, with plans to expand its branded portfolio and distribution. The company holds nine patents filed, five granted, and four under review, with 20 clinical trials ongoing. Manufacturing facilities in Dehradun and Kashipur are EU-GMP, CEP’s, USFDA, and NSF-GMP certified.
